Jan 8-11, 2018, JP Morgan Healthcare Conference, San Francisco, USA
Mar 12-14, 2018, BioEurope Sping, Amsterdam, Netherlands
- Merck Provides Upgraded Manufacturing Capabilities to BioInvent with Single-use Mobius® Bioreactors.
Read More >>
Read More >>
- Mobius 1000L Single Use Bioreactor
YouTube link >>
BioInvent has recently upgraded its facility increased capacity by adding new single use bioreactors up to 1000L. BioInvent Manufacturing is seeking clients requiring cGMP manufacturing services for clinical grade drug substance.
BioInvent Manufacturing, the contract manufacturing business unit of BioInvent International AB, has a proven track record for clients and partners since 1988 and over a 25 years’ history of inspections from regulatory authorities. Using single use technology for more than 25 years, BioInvent Manufacturing has produced drug substance for clinical trials in Europe, the USA, Japan and Australia. BioInvent is conveniently located just 40 minutes from Copenhagen International Airport.
The highly-experienced team at BioInvent Manufacturing provides flexibility and a proven collaborative approach to exceeding our client’s goals. Our process development team uses a platform process to ensure rapid and successful development of mammalian expression systems starting with technology transfer or cell line development to final release of drug substance.
BioInvent offers a range of cell line development options including through multiple partners.
Services available include:
- cGMP manufacturing of clinical drug substance up to 1000L using single use technology
- Cell line development
- Process development and process optimization
- cGMP cell bank preparation and storage
- Analytical development
- Formulation development
- cGMP protein stability studies
- Regulatory filing preparation
Contact Philip Wallace at firstname.lastname@example.org regarding your clinical manufacturing needs.